| 胆汁淤积性肝病诊断和治疗共识(2015) |
| |
| 引用本文： | 丁嘉欣, 杨婷婷, 江振洲, 张陆勇. 胆汁淤积性肝病潜在治疗药物研究进展[J]. 药学进展, 2018, 42(10): 772-779. |
| |
| 作者姓名： | 丁嘉欣 杨婷婷 江振洲 张陆勇 |
| |
| 作者单位： | 1.中国药科大学 江苏省新药筛选重点实验室，江苏 南京 210009;2.中国药科大学 教育部药品质量控制与药物警戒重点实验室，江苏 南京 210009;3.广东药科大学药学院 新药筛选与药效学评价中心，广东 广州 510006 |
| |
| 摘 要： | 胆汁淤积性肝损伤的发生伴随着胆汁酸稳态的失衡，蓄积的胆汁酸是肝损伤的直接诱因。胆汁酸转运蛋白与核受体通过调控胆汁酸水平维持机体胆汁酸稳态。从胆汁酸转运蛋白与核受体出发，系统介绍胆汁淤积性肝脏疾病治疗药物的最新进展，为胆汁淤积性肝损伤的治疗药物研发提供参考。
|
| 关 键 词： | 胆汁淤积 胆汁酸转运蛋白 核受体 新药研发 |
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection |
| |
| DING Jiaxin, YANG Tingting, JIANG Zhenzhou, ZHANG Luyong. Research Progress in Potential Therapeutic Drugs for Cholestatic Liver Diseases[J]. Progress in Pharmaceutical Sciences, 2018, 42(10): 772-779. |
| |
| Authors: | DING Jiaxin YANG Tingting JIANG Zhenzhou ZHANG Luyong |
| |
| Affiliation: | 1.Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China;2.Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China;3.Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China |
| |
| Abstract: | Cholestatic liver injury is usually accompanied by disordered homeostasis of bile acid, and the accumulation of bile acid is the direct cause of liver injury. Bile acid transporters and nuclear receptors maintain bile acid homeostasis by regulating the level of bile acid. This article systematically introduced the latest progress in the therapeutic drugs for cholestatic liver diseases from the perspectives of bile acid transporters and nuclear receptor, so as to provide reference for the development of related therapeutic drugs. |
| |
| Keywords: | cholestasis bile acid transporter nuclear receptor drug discovery |
|
| 点击此处可从《药学进展》浏览原始摘要信息 |
|
点击此处可从《药学进展》下载全文 |
|
